Paolo Tarantino

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

Paolo Tarantino
Nov 17, 2024, 01:10 | Blog
Paolo Tarantino: Moderating a Medscape symposium focused on HR+/HER2 at SABCS24
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn: "HR+/HER2- is…
Nov 16, 2024, 18:42 | Blog
Paolo Tarantino: Focusing on HR+/HER2- Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “HR+/HER2- is the…
Nov 13, 2024, 08:27 | Insight
Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent…
Nov 12, 2024, 18:55 | Insight
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by…
Nov 12, 2024, 18:43 | Insight
Paolo Tarantino: Could ADCs be safely administered subcutaneously?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Could ADCs…
Nov 7, 2024, 16:03 | Insight
The journey of ADCs is a story of perseverance
An article by Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., was recently…
Nov 6, 2024, 10:20 | Blog
Paolo Tarantino: Live discussion on the evolving role of ADCs across tumor histologies
Paolo Tarantino, Research Fellow at The Dana-Farber Cancer Institute, shared a post on X: "Join us tomorrow…
Nov 5, 2024, 15:59 | Blog
Elizabeth McKenna: The November issue of Cancer Discovery is now online
Elizabeth McKenna posted on X: "I'm so excited that the November issue of Cancer Discovery…
Nov 5, 2024, 15:51 | Blog
Paolo Tarantino: Honored to moderate the SABCS 2024 People’s Choice session
Paolo Tarantino posted on X: "Honored to moderate the SABCS 2024 People’s Choice session on…
Nov 4, 2024, 15:31 | Insight
Do patients with small ER+ tumors with high genomic risk benefit from chemotherapy?
An article by Florentine Hilbers, Postdoctoral Researcher at The Netherlands Cancer Institute, was recently mentioned by…
Nov 4, 2024, 14:04 | Insight
Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics
Raffaele Colombo shared a post on LinkedIn: "October was extremely busy yet incredibly rewarding: With Jamie…
Nov 4, 2024, 13:32 | Insight
Paolo Tarantino: The SERENA-2 phase 2 trial of camizestrant vs fulvestrant is out
Paolo Tarantino, Research Fellow at The Dana-Farber Cancer Institute, shared on X: “The SERENA-2 phase…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Nov 1, 2024, 07:37 | Blog
Paolo Tarantino: ADCs combine the potency of chemotherapy with the PK of mAbs
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "ADCs combine the potency…
Oct 29, 2024, 13:05 | Insight
Paolo Tarantino: My 100th scientific publication
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…
Oct 28, 2024, 08:58 | Insight
Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…
Oct 27, 2024, 11:29 | Blog
Behind the Journey of ADCs by Raffaele Colombo
Raffaele Colombo posted on X about recent paper by him as first author titled "The…
Oct 26, 2024, 15:59 | Insight
Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs
Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post…
Oct 26, 2024, 12:57 | Societies
Highlights from the 36th EORTC-NCI-AACR Symposium 2024
The 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held at the…
Oct 26, 2024, 11:58 | Blog
Jennifer Wargo on immunotherapy and microbiome at ENA Symposium 2024
Paolo Tarantino shared a post on X: ''Wonderful ENA Symposium 2024 keynote lecture on immunotherapy…
Oct 26, 2024, 09:26 | Blog
Paolo Tarantino: Honored to co-chair the New Drugs on the Horizon Session at the EORTC-NCI-AACR Triple Meeting
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn: "Such a honor to…
Oct 25, 2024, 16:47 | Blog
Key milestones and insights from the evolution of antibody-drug conjugates - Zymeworks Inc.
Zymeworks Inc. shared a post on Linkedin: ''We're proud to share a recent publication in…
Oct 25, 2024, 15:45 | Blog
Paolo Tarantino: Rational KRAS inhibitor combinations by Sandra Misale at ENA Symp 24
Paolo Tarantino, Research Fellowship Scholar at Dana-Farber Cancer Institute, shared a post on X: "Terrific talk…
Oct 25, 2024, 13:16 | Insight
Elizabeth McKenna: An overview of the past 4 decades of development of ADC’s
Elizabeth McKenna, Executive Editor of Cancer Discovery at American Association for Cancer Research, shared on…
Oct 25, 2024, 11:48 | Blog
Paolo Tarantino: Anticipated evolutions in the assessment of MRD to guide cancer treatment
Paolo Tarantino shared a post on X: ''ENASymp24 day 3: Heather Parsons from Dana-Farber’s Breast…
Oct 25, 2024, 11:41 | Blog
Raffaele Colombo: Honored to discuss ADCs at the ENASymp24
Raffaele Colombo shared a post by Sandra Misale, Assistant professor at Sidney Kimmel Comprehensive Cancer…
Oct 25, 2024, 08:51 | Blog
Nirmit Kumar: Great overview of the history of Antibody Drug Conjugates by Raffaele Colombo et al.
Nirmit Kumar, Senior Global Medical Strategy Leader at AstraZeneca, shared a post by Paolo Tarantino…
Oct 23, 2024, 14:45 | Blog
Paolo Tarantino: How do we build a new generation of safer and more active ADCs for treating cancer
Paolo Tarantino and Raffaele Colombo shared posts on X, about recent paper published in Cancer…
Oct 23, 2024, 10:40 | Insight
Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared…
Oct 22, 2024, 10:18 | Blog
An extensive overview on precision medicine by Paolo Tarantino and Sara Tolaney
Florez Lab shared a post on X: ''Dr. Paolo Tarantino and Dr. Sara Tolaney are…
Oct 21, 2024, 19:21 | Blog
ESMO E-Learning: Management of HER2-Low Breast Cancers by Paolo Tarantino
Paolo Tarantino shared a post on LinkedIn: ''Our understanding of HER2-low expression as a biomarker…
Oct 21, 2024, 15:09 | Insight
Highlights from the 6th Annual Precision Medicine Symposium
The 6th Annual Precision Medicine Symposium took place from October 18th and 19th 2024. It…
Oct 20, 2024, 19:09 | Insight
Paolo Tarantino: Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared on LinkedIn: “Precision medicine for HR+…
Oct 20, 2024, 18:31 | Blog
Paolo Tarantino: Terrific TNBC session in Hudson, NY
Paolo Tarantino shared the following on LinkedIn: “Terrific TNBC session in Hudson, NY. I had…
Oct 19, 2024, 16:37 | Drugs
Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S. market
Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it…
Oct 17, 2024, 18:06 | Insight
Paolo Tarantino: We cure breast cancer every day better
Paolo Tarantino shared a post on LinkedIn: "The latest EBCTCG meta-analysis of over 150.000 patients…
Oct 17, 2024, 15:58 | Insight
Paolo Tarantino: We desperately need a biomarker to refine treatment for early-stage TNBC
Paolo Tarantino shared a post on X about a recent paper by M. Martín et…
Oct 13, 2024, 17:58 | Blog
Raffaele Colombo: Excited to be presenting ADCs at the 36th ENA symposium
The 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will be held in person…
Oct 12, 2024, 14:35 | Blog
Paolo Tarantino: EBCTCG analysis of breast cancer patients outcomes over two decades
Paolo Tarantino shared on X: "What is the actual impact of breast cancer clinical research…
Oct 12, 2024, 10:30 | Insight
FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib…
Oct 11, 2024, 13:35 | Insight
Paolo Tarantino: ADCs bring us together in the fight against cancer
Paolo Tarantino shared a post on X: “ADCs bring us together in the fight against…
Oct 11, 2024, 08:15 | Insight
Managing ADC Toxicities on Lung Cancer Considered
IASLC shared a post on X: “Anti Drug Conjugates represent a new way of treating…
Oct 9, 2024, 16:03 | OncoDaily Pulse
Inside OncoDaily Party Barcelona
On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in Barcelona, Spain.…
Oct 8, 2024, 17:26 | Insight
Paolo Tarantino: The largest HER2-low sub-analysis of a RCT led by Guilherme Nader-Marta
Paolo Tarantino shared a recent article by Guilherme Nader-Marta et al. published in Breast Cancer…
Oct 4, 2024, 15:15 | Blog
Paolo Tarantino: An interesting biomarker study of DB04. Two notable findings at ESMO24
Paolo Tarantino shared a post on X: "Among the many great ESMO24 posters there was…
Oct 4, 2024, 15:09 | Blog
Phase 3 EVER-002 trial is out
Paolo Tarantino shared an article by Binghe Xu on X: "Phase 3 EVER-002 trial (also…
Oct 4, 2024, 10:15 | Blog
The first prospective trial of sacituzimab govitecan (+ trastuzumab) after T-DXd for HER2+ MBC
Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X, adding: "There’s few open questions as…
Oct 1, 2024, 18:35 | Blog
Paolo Tarantino: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present
Paolo Tarantino shared on X: "Conjugated Antibodies: A Bridge Between Chemotherapy of the Past and…
Oct 1, 2024, 17:18 | Blog
Paolo Tarantino: Feels like yesterday when I first stepped into Dana-Farber Cancer Institute
Paolo Tarantino shared a post on X: "It feels like yesterday when I first stepped…
Oct 1, 2024, 09:29 | Blog
Paolo Tarantino's ESMO24 top 5 breast cancer presentations and takeaway messages
Paolo Tarantino shared a post by Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, on X, adding:…
Sep 29, 2024, 15:48 | Blog
Elisabetta Bonzano: Dual HER2 inhibition, mechanisms of synergy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: "Dual HER2 inhibition:…
Sep 29, 2024, 15:43 | Blog
Paolo Tarantino: The ratio of enrollment to industry-sponsored trials has doubled between 2008-2022
Paolo Tarantino shared the following on X: “Out in JCO: the ratio of enrollment to…
Sep 28, 2024, 14:00 | Blog
Paolo Tarantino: How do the results of DESTINY-Breast06 change our practice?
Paolo Tarantino shared on LinkedIn: "How do the results of DESTINY-Breast06 change our practice? Should…
Sep 26, 2024, 16:11 | Blog
Chandler Park: Learning the latest cutting edge data to help our cancer patients at ESMO 24
Chandler Park shared a post on Linkedin: ''ESMO was FUN! Loved learning the latest cutting…
Sep 26, 2024, 14:19 | Blog
Paolo Tarantino: ADC stability does not equal ADC tolerability
Paolo Tarantino shared a post by Raffaele Colombo, on X, adding: ''Antibody-drug conjugate (ADC) stability…
Sep 26, 2024, 14:07 | Blog
Paolo Tarantino: Why didn’t Datopotamab Deruxtecan improve OS in HR+/HER2- metastatic breast cancer
Paolo Tarantino shared a post on X: ''Why didn’t Datopotamab Deruxtecan improve overall survival in hormone…
Sep 23, 2024, 16:12 | Insight
Giuseppe Banna: How ADCs are revolutionizing patient outcomes in real-time
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn: “Join…
Sep 23, 2024, 11:36 | Blog
OncoDaily Party Barcelona
On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in…
Sep 23, 2024, 09:00 | Insight
Theodoros Kontoulis: Heterogeneity of residual disease (RD) after NACT in breast cancer
Theodoros Kontoulis shared on LinkedIn: “Most viewed in the last 7 days from JAMA Oncology:…
Sep 21, 2024, 01:25 | Insight
Paolo Tarantino: 10 facts to know to prepare for the rise of ADCs
Paolo Tarantino shared on X: “ADCs are among the most rapidly expanding treatment modalities in…
Sep 20, 2024, 06:22 | Blog
Paolo Tarantino: Steroids are the mainstay for treating ADC-induced ILD
Paolo Tarantino shared a post on X by Sarah Sammons adding: "Agree! Steroids are the…
Sep 19, 2024, 15:18 | Insight
Paolo Tarantino: Monitoring ADC-related interstitial lung disease
Paolo Tarantino shared a post on LinkedIn: "More sensitive ways are needed to monitor for ADC-related…
Sep 19, 2024, 04:32 | Societies
Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 18, 2024, 23:03 | Insight
Aleix Prat: Dual HER2 inhibition in Breast Cancer
Aleix Prat shared a post on X about a recent paper by Adrienne Waks et…
Sep 18, 2024, 14:24 | Blog
Paolo Tarantino: ESMO’s environmental commitment
Paolo Tarantino shared a post on X: "Inspiring to see The European Society for Medical Oncology…
Sep 18, 2024, 00:08 | Insight
Paolo Tarantino: Testing T-DXd vs chemo for endocrine-refractory HR+ MBC
Paolo Tarantino shared a post on X: "Previously presented at ASCO24 by Giuseppe Curigliano, the impressive…
Sep 17, 2024, 16:17 | Blog
Paolo Tarantino: Forever grateful to mentor and friend Joey Curigliano
Paolo Tarantino posted the following on X: “Here’s to a mentor, a friend, a fierce…
Sep 17, 2024, 15:03 | Societies
Are you presenting a Poster at ESMO24?
  The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 17, 2024, 10:01 | Blog
Paolo Tarantino: Terrific ending for ESMO24 day one
Paolo Tarantino shared a post on X: "Terrific ending for ESMO24 day one, getting to…
Sep 17, 2024, 09:06 | Blog
Paolo Tarantino: Gene signatures have revolutionized treatment for HR+ eBC
Paolo Tarantino shared on X: "Gene signatures have revolutionized treatment for HR+ eBC. Could they…
Sep 16, 2024, 19:46 | Insight
Paolo Tarantino: A visit to the SOLTI headquarters at ESMO24
Paolo Tarantino shared on LinkedIn: “ No better way to kick off ESMO24 Barcelona than…
Sep 16, 2024, 04:57 | Blog
The latest insights on ADCs for HR-Positive, HER2-low metastatic breast cancer - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: ''Paolo Tarantino will discuss the latest…
Sep 15, 2024, 08:33 | Drugs
Paolo Tarantino: Some HER2+ tumors melt upon dual anti-HER2 Treatment
Paolo Tarantino shared on X: "Some HER2+ tumors melt upon dual anti-HER2 Treatment; others require…
Sep 14, 2024, 19:28 | Insight
Paolo Tarantino: Are all residual diseases equal?
Paolo Tarantino shared on LinkedIn: “ Patients with residual breast cancer after neoadjuvant treatment harbor…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 14, 2024, 06:35 | Opinion
Paolo Tarantino: Interesting data with TROP2 quantitative continuous scoring to predict Dato-DXd activity in lung cancer
Paolo Tarantino posted the following on X: “Interesting data with TROP2 quantitative continuous scoring (QCS)…
Sep 13, 2024, 07:23 | Blog
Paolo Tarantino: List for the upcoming early-phase ADCs at ESMO24
Paolo Tarantino shared a post by Raffaele Colombo on X, adding: "Terrific list of ADC data to…
Sep 10, 2024, 06:01 | Insight
Paolo Tarantino: A Special Collection for ADCs in Breast Oncology for Nature Portfolio
Paolo Tarantino shared on LinkedIn: "The field of ADCs is still at its dawn. Many…
Sep 7, 2024, 19:36 | Insight
A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…
Sep 7, 2024, 11:16 | Drugs
Paolo Tarantino: Recommended read on adjuvant ribociclib in preparation for the ESMO24
Oncology Brothers shared a post by Paolo Tarantino on X, adding: “Adjuvant abemaciclib preferred for…
Sep 7, 2024, 10:06 | Blog
Is adjuvant ribociclib ready for prime time?
Sarah Sammons shared a post by Paolo Tarantino, on X: "The number needed to treat (NNT) to…
Sep 6, 2024, 11:25 | Insight
Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC
Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…
Sep 5, 2024, 15:22 | Blog
Paolo Tarantino: Looking forward to join the Medscape symposium to review treatment landscape for HR+/HER2- metastatic breast cancer
Paolo Tarantino shared a post on LinkedIn: "Really looking forward to joining this Medscape symposium to…
Sep 4, 2024, 15:08 | Blog
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
Paolo Tarantino shared a post on LinkedIn: "Two weeks to ESMO 2024. Multiple important breast…
Sep 4, 2024, 14:21 | Blog
ESMO 2024 Research Fellowship awardees
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is pleased…
Aug 18, 2024, 07:29 | Blog,Opinion
Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?
Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…
Aug 12, 2024, 14:48 | Blog
Global study on the accuracy of HER2-low diagnoses among 77 pathologists from 14 countries
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute shared a recent article by Josef…
Aug 9, 2024, 02:21 | Insight
Paolo Tarantino: Interesting sub analysis from the SENOMAC trial
Paolo Tarantino shared on X about a recent paper by Jana de Boniface et al.…
Aug 9, 2024, 02:19 | Blog
Activity of T-DXd in HER2-expressing Biliary Tract Cancer
Paolo Tarantino shared on X: "Activity of T-DXd in HER2-expressing BTC published in Journal of Clinical…
Aug 7, 2024, 16:50 | Blog
The recipients of the 2024 ESMO Society Awards
The 2024 ESMO Society Awards have been announced on 6th August by ESMO. ESMO recently…
Aug 7, 2024, 00:27 | Blog
Paolo Tarantino reflects on the results from DESTINY-CRC02 published in the Lancet Oncology
Paolo Tarantino shared on X: “Results from DESTINY-CRC02 published in the Lancet Oncology. Among patients…
Aug 3, 2024, 07:34 | Blog
Paolo Tarantino: When diagnosing ILD, the radiologist is your best friend
Paolo Tarantino shared on LinkedIn: "When diagnosing Interstitial Lung Disease (ILD), the radiologist is your…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 25, 2024, 00:29 | Blog
Paolo Tarantino: Thanks to The ASCO Post for featuring my ADC talk at IBC East
Paolo Tarantino shared a post by The ASCO Post, on X, adding: ''Thanks to The ASCO…
Jul 23, 2024, 08:25 | Blog
Paolo Tarantino: HER2: a remarkable story of precision oncology
Paolo Tarantino shared on X: "HER2: a remarkable story of precision oncology. Check this wonderful Nature…
Jul 21, 2024, 09:23 | Blog
Paolo Tarantino: We just see the tip of the iceberg of how ADCs work
Paolo Tarantino shared on X:            . "On my way to…
Jul 20, 2024, 11:01 | Insight
Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…
Jul 19, 2024, 00:40 | Insight
Paolo Tarantino: Wonderful explanation on how T-DXd/Enhertu work for the treatment of breast cancer
Paolo Tarantino shared a post by Liz O'Riordan on X, adding: "Wonderful explanation for patients…
Jul 15, 2024, 04:50 | Insight
Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal
Paolo Tarantino, shared a post on LinkedIn about a recent paper titled "Antibody–drug conjugates: Smart…
Jul 14, 2024, 21:42 | Blog
Paolo Tarantino: Stellar Tumor Board session at the Harvard Medical School Breast Course
Paolo Tarantino shared a post on X: ''Stellar Tumor Board session at the Harvard Medical…
All: 273 Posts: 1 - 100
Special Coverage